The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer

1991 ◽  
Vol 23 (6) ◽  
pp. 559-567 ◽  
Author(s):  
L. Samodai ◽  
L. Kiss ◽  
Z. Kolozsy ◽  
L. Mohácsi
2012 ◽  
Vol 1 (3) ◽  
Author(s):  
Vincent Fradet ◽  
Christiane Gaudreau ◽  
Paul Perrotte ◽  
Jean Côté ◽  
Jean-Marie Paquin

Intravesical bacille Calmette-Guérin (BCG) therapy is the most effective treatmentfor high-risk superficial bladder cancer. Severe systemic complications are rare, but may occur in approximately 1% of cases. We report a severe complicationof intravesical BCG: a disseminated Mycobacterium bovis infectionwith biopsy-proven granulomatous hepatitis in a patient with bladder cancer. We also elaborate on the different management alternatives.


Author(s):  
Nejla El amri ◽  
Héla Zeglaoui ◽  
Salma Hmila ◽  
dhouha khalifa ◽  
Sadok Lataoui ◽  
...  

BCG intra-vesical instillation is the standard of care for superficial bladder cancer at high risk of relapse and progression. Yet, this treatment can cause dysimmune complications. Osteoarticular manifestations related to BCG therapy are rare and frequently mild. We report a rare case of a severe form successfully treated with Rituximab.


Cancer ◽  
1995 ◽  
Vol 76 (5) ◽  
pp. 833-839 ◽  
Author(s):  
John A. Freeman ◽  
David Esrig ◽  
John P. Stein ◽  
Anne R. Simoneau ◽  
Eila C. Skinner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document